Pharmaceuticals, Biotechnology and Life Sciences
The University of Alabama at Birmingham (UAB) and Mereo BioPharma Group plc (NASDAQ: MREO), today announced top-line data from a Phase 1b/2 clinical trial evaluating alvelestat, a novel, orally active Neutrophil Elastase (NE) inhibitor in hospitalized COVID-19 Respiratory Disease patients.
Mereo BioPharma on Thursday announced the completion of a $70 million (£56 million) private placement (the “Fundraising”) with a number of new and existing U.S based institutional and accredited investors.
Mereo BioPharma has entered into a Securities Purchase Agreement with a new U.S.-based institutional healthcare investor. Under the terms of the Agreement, the institutional investor has agreed to make an investment of $3 million to purchase 12,252,715 of the Company’s ordinary shares (equivalent to 2,450,543 American Depository shares (ADSs)) at a price equivalent to 18.8 pence per share, which represents a 20% discount over Mereo’s closing share price of 23.5 pence on AIM on February 18, 2020.
Mereo Biopharma has reported £16.2m net loss after tax for the six-month period for 2019, the company said in a press release announcing conference call.
Mereo BioPharma will present the 6-month interim data from the open label arm of the its Phase 2b dose-ranging clinical study of setrusumab (BPS-804) in adults with Type I, III or IV osteogenesis imperfecta (OI) at the upcoming American Society for Bone and Mineral Research (ASBMR) 2019 Annual Meeting to be held from September 20-23 in Orlando, FL.
Mereo BioPharma on Tuesday presented positive data after testing BGS-649, oral inhibitor aromatase treatment of hypogonadotropic hypogonadism (HH) for obese…
Mereo BioPharma Group has finished £10 million tranche of the credit loan set up in August 2017 with Silicon Valley…
Mereo BioPharma has made a deal with AstraZeneca for an exclusive license, including an option to acquire, AZD9668, an oral inhibitor…
IDMC has recommended that all three doses continue to be tested in the ongoing Phase 2b trial for BGS-649, an inhibitor for obese men with hypogonadotropic hypoganadism.
Mereo BioPharma’s bone disease drug BPS-804 has been accepted to participate in the European Medicines Agency’s (EMA) Adaptive Pathways programme.